Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|December 5, 2024

Setting Patient Expectations and Use of Combination Treatment for Hidradenitis Suppurativa

Author(s)Jennifer Hsiao, MD, Rani Cooper, MD

Panelists discuss how managing patient expectations while implementing combination treatment approaches can optimize outcomes in hidradenitis suppurativa, emphasizing the importance of clear communication about treatment goals and timelines.

Episodes in this series

3 experts in this video

EP. 1 Burden of Hidradenitis Suppurativa on Patients and Diagnostic Challenges

3 experts in this video

EP. 2 Efficacy and Safety of Current Treatments for HS

3 experts in this video

EP. 3 Future Innovations for HS Diagnosis and Management

3 experts in this video

EP. 4 Dosing Considerations and Assessing the Efficacy of Treatment

3 experts in this video

EP. 5 Potential Role of AI in HS Diagnosis

2 experts in this video

EP. 6 Early Recognition and Use of Biologics to Manage Hidradenitis Suppurativa

2 experts in this video

EP. 7 Setting Patient Expectations and Use of Combination Treatment for Hidradenitis Suppurativa

2 experts in this video

EP. 8 Treatment Switches and the Future of Hidradenitis Suppurativa Management

EP. 9 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 1

EP. 9 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 1

EP. 10 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 2

EP. 10 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 2

EP. 11 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 3

EP. 11 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 3

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

MAIC Evaluates 1-Year Outcomes of Biologics in HS

ByMaddi Hebebrand, MC, Associate Editor

February 2nd 2026

Patient Perspectives Reveal the Hidden Burden of Drainage in HS

ByMaddi Hebebrand, MC, Associate Editor

January 29th 2026

Steroid Stewardship during Infant Flare

ByAdam Friedman, MD, FAAD,Lawrence Eichenfield, MD,Alexandra K. Golant, MD

January 28th 2026

Case Study 2: Managing Severe Infant Flares

ByAdam Friedman, MD, FAAD,Lawrence Eichenfield, MD,Alexandra K. Golant, MD

January 28th 2026

Case-Based Perspectives on Biologic Treatment for Hidradenitis Suppurativa

ByKaitlyn Bader, Assistant Managing Editor

January 22nd 2026

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Trending on Dermatology Times

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

Introducing Dermatology Times NP/PA Connect